Revascularization Should Not Be Endpoint For GP IIb/IIIa Inhibitors - Cmte.

18 Oct 1999

• By The Pink Sheet

Urgent revascularization should not be included in composite endpoints for active controlled trials of new glycoprotein IIb/IIIa inhibitors, the Cardiovascular & Renal Drugs Advisory Committee agreed Oct. 14.

Revascularization Should Not Be Endpoint For GP IIb/IIIa Inhibitors - Cmte.

More from Archive

More from Pink Sheet